​

MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

OverviewForecastFinancialsChartTranscripts

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 1.35% institutional investors, 10.85% insiders, and 87.80% retail investors. Bvf inc/il is the largest institutional shareholder, holding 31.21% of MLTX shares. Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund, with 1.65% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMoonLake Immunotherapeutics1.35%10.85%87.80%
SectorHealthcare Stocks 232.86%10.65%-143.51%
IndustryBiotech Stocks 382.13%10.41%-292.54%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il19.75M31.21%$141.62M
Avoro capital advisors2.00M3.16%$14.34M
Cormorant asset management, lp1.99M3.15%$14.30M
Jane street group1.68M2.65%$22.17M
Adage capital partners gp1.50M2.37%$10.76M
Morgan stanley1.04M1.65%$13.77M
Schonfeld strategic advisors965.40K1.53%$6.92M
Jpmorgan chase837.74K1.32%$11.04M
Price t rowe associates inc /md/822.96K1.30%$5.90M
Fmr726.93K1.15%$5.21M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il19.75M5.74%$141.62M
Ghost tree capital300.00K4.13%$13.19M
Lion point capital, lp67.50K2.75%$483.98K
Cormorant asset management, lp1.99M0.99%$14.30M
Boxer capital management250.00K0.57%$1.79M
Eagle health investments lp187.60K0.54%$2.47M
Rhenman & partners asset management ab364.00K0.45%$4.80M
Ikarian capital435.84K0.32%$3.12M
First turn management262.64K0.28%$1.88M
Caitong asset management7.09K0.26%$93.51K

Top Buyers

HolderShares% AssetsChange
Jane street group1.68M0.00%1.66M
Adage capital partners gp1.50M0.02%1.50M
Schonfeld strategic advisors965.40K0.04%965.40K
Morgan stanley1.04M0.00%787.93K
Jpmorgan chase837.74K0.00%663.58K

Top Sellers

HolderShares% AssetsChange
Cormorant asset management, lp1.99M0.99%-6.50M
Fmr726.93K0.00%-5.00M
Avoro capital advisors2.00M0.19%-2.15M
Price t rowe associates inc /md/822.96K0.00%-1.79M
Westfield capital management co lp---1.26M

New Positions

HolderShares% AssetsChangeValue
Adage capital partners gp1.50M0.02%1.50M$10.76M
Ikarian capital435.84K0.32%435.84K$3.12M
Soleus capital management400.00K0.19%400.00K$5.27M
Boothbay fund management258.78K0.03%258.78K$1.86M
Boxer capital management250.00K0.57%250.00K$1.79M

Sold Out

HolderChange
Ifp advisors-1.00
National bank of canada /fi/-2.00
True wealth design-5.00
Gamma investing-6.00
Montag a & associates-7.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Dec 31, 202517-90.17%854,269-97.72%10.04%13-85.71%3-93.33%
Sep 30, 202530-79.31%901,952-98.46%10.02%17-73.02%9-83.64%
Jun 30, 2025145-2.03%58,588,368-0.85%921.06%63-11.27%5425.58%
Mar 31, 202515019.05%59,722,976-5.57%940.93%72-4343.33%
Dec 31, 20241246.90%63,224,5991.80%1001.03%70-3020.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
Jupiter Merian Glb Eq AbsRet I USD Acc1.18M1.65%1.18M
Polar Capital Biotech S Inc1.00M1.58%-
Fidelity Growth Compy Commingled Pl S981.02K1.54%273.63K
T. Rowe Price Health Sciences1.00M1.40%253.67K
Fidelity Growth Company Fund740.92K1.17%248.13K
Federated Hermes Kaufmann Growth665.00K1.05%-
Federated Hermes Kaufmann R665.00K1.05%-
US Small-Cap Growth II Equity Comp523.89K0.83%-134.19K
Fidelity Select Health Care520.00K0.82%-150.00K
Federated Hermes Kaufmann Small Cap A503.00K0.79%-16.00K

Recent Insider Transactions

DateNameRoleActivityValue
Apr 14, 2026Bodenstedt Matthias Chief Financial OfficerSell$47.45K
Apr 13, 2026Santos da Silva Jorge Chief Executive OfficerSell$945.64K
Apr 10, 2026Santos da Silva Jorge Chief Executive OfficerSell$1.81M
Apr 09, 2026Bodenstedt Matthias Chief Financial OfficerSell$1.63M
Apr 10, 2026Bodenstedt Matthias Chief Financial OfficerSell$37.56K

Insider Transactions Trends

DateBuySell
2026 Q2-5
2026 Q1-3
2025 Q414
2025 Q3-6
2025 Q2--

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 1.35%, followed by 10.85% insiders and 87.80% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 382.13%, which MoonLake Immunotherapeutics falls below.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (19.75M shares, 31.21%), Avoro capital advisors (2M shares, 3.16%), and Cormorant asset management, lp (1.99M shares, 3.15%). Together, they hold 37.52% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 5.74% of its assets in 19.75M MoonLake Immunotherapeutics shares, valued at 141.62M$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

Jupiter Merian Glb Eq AbsRet I USD Acc is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 1.65% of its total shares outstanding invested in 1.18M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools